Ra Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2008-01-01
- Employees
- 89
- Market Cap
- -
- Website
- http://www.rapharma.com
Clinical Trials
26
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Ra Pharmaceuticals, Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT04115293
- Locations
- 🇺🇸
Site 41: Diagnostic and Medical Clinic, Mobile, Alabama, United States
🇺🇸Site 116: Neuromuscular Clinic and Research Center, Phoenix, Arizona, United States
🇺🇸Site 4: University of Southern California, Los Angeles, California, United States
Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
- Conditions
- Immune Mediated Necrotizing Myopathy
- Interventions
- Other: Placebo
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Ra Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT04025632
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸University of Florida Health Jacksonville, Jacksonville, Florida, United States
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Ra Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT03315130
- Locations
- 🇺🇸
Diagnostic and Medical Clinic - Mobile, Mobile, Alabama, United States
🇺🇸The Research Center of Southern California, Carlsbad, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Ra Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03225287
- Locations
- 🇺🇸
Investigative Site 4, Los Angeles, California, United States
🇺🇸Investigative Site 19, Dallas, Texas, United States
🇦🇺Investigative Site 3, Gosford, Australia
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Ra Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT03078582
- Locations
- 🇬🇧
Investigative Site, London, United Kingdom
- Prev
- 1
- 2
- Next